Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02139020
  4. Details
NCT02139020 Clinical Trial

Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients

Squamous Cell Carcinoma of the Head and Neck Clinical Trial

Official title:
Prospective Collection of Plasma Samples From Patients Treated With Molecular Targeted Therapies for Squamous Cell Carcinoma of the Head and Neck

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT02139020
Other study ID # UCL-ONCO 2013-01
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 2013
Est. completion date January 2033

Study information
Verified date December 2023
Source Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Contact Jean-Pascal Machiels, MD, PhD
Phone 0032 2 764
Email jean-pascal.machiels@uclouvain.be
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The investigators will collect plasma samples at baseline, during treatment, and at progression.

Description:

In this study, the investigators will collect plasma samples at baseline, during treatment, and at progression. This plasma bank will be used to study the potential value of some biomarkers to predict treatment activity or resistance to cetuximab or other targeted agents

Recruitment information / eligibility
Status Recruiting
Enrollment 400
Est. completion date January 2033
Est. primary completion date January 2033
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - patients treated with radiation therapy and cetuximab according to Bonner et al - patients treated with cetuximab in combination with chemotherapy according to Vermorken et al. - patients treated with a molecular targeted agent as a part of a clinical study Exclusion Criteria: - patients with another type of head and neck cancer - patients non treated with targeted therapies

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Plasma samples
Plasma samples at baseline (and one whole blood sample) and at every radiological evaluations

Locations
Country Name City State
Belgium Grand Hôpital de Charleroi Charleroi Hainaut
Belgium Centre Hospitalier Jolimont-Lobbes-Nivelles-Tubize Haine-Saint-Paul
Belgium CHU Liège Liège
Belgium Clinique et Maternité Sainte-Elisabeth Namur
Belgium Clinique Saint-Pierre Ottignies Brabant Wallon

Sponsors (1)
Lead Sponsor Collaborator
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Country where clinical trial is conducted

Belgium, 

Outcome
Type Measure Description Time frame Safety issue
Primary Prospective storage of plasma samples of patients treated with cetuximab or other targeted agents All the analyses will be done when we have enough of collected samples one year after the collection
See also
  Status Clinical Trial Phase
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Recruiting NCT06236464 - Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas
Terminated NCT04659369 - Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC Phase 1
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT02572778 - Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer
Terminated NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1
Terminated NCT01488318 - Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma Phase 2
Active, not recruiting NCT00999700 - Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin Phase 3
Completed NCT02565758 - ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors Phase 1
Completed NCT02543476 - SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) N/A
Recruiting NCT03938012 - Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma
Terminated NCT02124850 - A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab Phase 1
Active, not recruiting NCT03313804 - Priming Immunotherapy in Advanced Disease With Radiation Phase 2
Recruiting NCT05208762 - A Study of SGN-PDL1V in Advanced Solid Tumors Phase 1
Terminated NCT04453046 - Hemopurifier Plus Pembrolizumab in Head and Neck Cancer N/A
Completed NCT01758731 - Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History Phase 1
Completed NCT02473731 - A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients Phase 1
Completed NCT02022098 - Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial N/A
Completed NCT01458392 - Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck Phase 2
Completed NCT02882308 - Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck. Phase 2